Electra Therapeutics Inc.

Electra Therapeutics Inc. is focused on clinical research in secondary hemophagocytic lymphohistiocytosis (sHLH), with attention to the severe inflammatory and immune dysregulation seen in this rare condition. Its active trial program includes participants with macrophage hemophagocytic lymphohistiocytosis (mHLH) linked to lymphoma, reflecting interest in complex hematologic and immune-mediated disease settings.

• Immune hyperinflammation
• Hemophagocytic syndromes
• Hematologic malignancy-associated inflammation

The sponsor’s research activity in this area is centered on clinical needs where immune activation and underlying cancer triggers intersect, particularly within specialized hematology and oncology care environments.